🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🧬 Liquid Biopsy in Clinical Practice: Past, Present & Future🩸 A new review explores the evolution, applications, and future directions of liquid biopsy in oncology. Here are the key insights: 🔬Technologies & Biomarkers ✅ Circulating Tumor Cells (CTCs) – Enrichment &

SCROTAL TEP + IPP VIDEO youtu.be/cj3mRui4c4w?si… via YouTube

Check our new study🗞️ #RoboticSurgery for prostate cancer (RARP), revealing variability in surgical techniques across institutions. 🤔 Could this insight lead to standardized best practices & improved patient outcomes? #AIinSurgery Ketan K. Badani MD Link: trebuchet.public.springernature.app/get_content/d7…

"In 1992, the Medicare conversion factor was $31.00. Today? $32.36. That’s a $1.36 total increase in 33 YEARS. If it had just kept up with inflation, it would be over $64.00 today. Instead, it’s more than 50% below where it should be."

CRITICAL UPDATE: Medicine is at a crossroads. Physicians are now moving to employment over private practice due to overburdensome regulations and financial incentives to do so. Facilities can pay doctors significantly more than they make in private practice and this increased

MI2- MINIMALLY INVASIVE PENILE PROSTHESIS INSERTION youtu.be/5HzV7giVvCA?si… via YouTube

It’s heating up. Stellar group debate on establishing best training metrics for #singleport extraperitoneal prostatectomy #AUA2025 #ORSI Mutahar Ahmed Alex Mottrie Lee Zhao Reza Mehrazin, MD Shirin Razdan, M.D. Mutahar Ahmed Ram Pathak, M.D. Michael Stifelman and many others

Happy to be a small part of this eminent group. 🙏🏻 #sprocks

From favorite junior residents to favorite robotic fellows. Catching up at #AUA25 with Benjamin Eilender and #joshy has been a joy. 🤖👯‍♀️👯‍♂️

Great morning yesterday presenting alongside these fellow Rising Stars 💫at the Intuitive Robotics Theater Prostate Session. Thank you Michael Stifelman Drew Wagner Richard Link David Jiang Peter Chang Arie Carneiro for a thoughtful discussion and helpful tips. ✅

🔥 New GSM Guidelines 🔥 Genitourinary Syndrome of Menopause is common, progressive, & treatable. The 2025 AUA Guidelines make it crystal clear: ✅ Ask about symptoms ✅ Vaginal estrogen = first-line ✅ Read all guidelines here: tinyurl.com/2anhyr6u 1/2

Honored to stand alongside Dr. Jasmin Katrin Badawi as winners of the AUA Retrospectroscope Award. Proud of my work on The History of the Hijra, a very unique topic that I learned a lot about. I’m still looking for a journal to publish if anyone is interested! Amer. Urol. Assn.

HOT OFF THE PRESS New JAMA Surgery original article from our team Surgical Performance Metrics for 1-Year Patient-Reported Outcomes After Radical Prostatectomy. Using performance metrics (technical skills and surgical gestures) collected from videos, we are able to anticipant

Medicare’s message to doctors: “Do more, get paid less.” 2025 conversion factor: $32.35 2015 conversion factor: $35.93 A decade of cuts while demands explode. This isn’t reform—it’s sabotage. In 2025, the Medicare conversion factor will be lower than it was in 2015. A decade

A supportive call with your mom is better for you than texting. When daughters faced anxiety, if they heard their mother's voice rather texting, their bodies expressed fewer stress hormones and more love hormones. A mother's love is felt through her tone as well as her words.

Use of local estrogen therapy among breast cancer patients #ASCO25 abstract Retrospective cohort study of 18,620 breast cancer pts 65+ showed local vaginal estrogen users (n=800) had ⭐️improved ⭐️overall survival!! OncoAlert ascopubs.org/doi/10.1200/JC…

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

The most practice changing trial from #ASCO25 is now live on NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. Perfect case example of a #cancergroundshot trial.